Cargando…
Clinical Outcomes of Tigecycline in the Treatment of Multidrug-Resistant Acinetobacter baumannii Infection
PURPOSE: Acinetobacter baumannii (A. baumannii) has emerged as a major cause of nosocomial pneumonia and sepsis in seriously ill patients. Multidrug-resistant A. baumannii (MDRAB) is increasing in frequency, and the management of it's infections is consequently difficult. Therefore, tigecycline...
Autores principales: | Shin, Jung Ar, Chang, Yoon Soo, Kim, Hyung Jung, Kim, Se Kyu, Chang, Joon, Ahn, Chul Min, Byun, Min Kwang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Yonsei University College of Medicine
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3423844/ https://www.ncbi.nlm.nih.gov/pubmed/22869481 http://dx.doi.org/10.3349/ymj.2012.53.5.974 |
Ejemplares similares
-
Tigecycline-based versus sulbactam-based treatment for pneumonia involving multidrug-resistant Acinetobacter calcoaceticus-Acinetobacter baumannii complex
por: Ye, Jung-Jr, et al.
Publicado: (2016) -
Resistance mechanisms of tigecycline in Acinetobacter baumannii
por: Sun, Chunli, et al.
Publicado: (2023) -
Characterization of Increased Extracellular Vesicle-Mediated Tigecycline Resistance in Acinetobacter baumannii
por: Cho, Hyejin, et al.
Publicado: (2023) -
In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii
por: Principe, Luigi, et al.
Publicado: (2009) -
Sensitivity of levofloxacin in combination with ampicillin-sulbactam and tigecycline against multidrug-resistant Acinetobacter baumannii
por: Madadi-Goli, Nahid, et al.
Publicado: (2017)